- Home
- SGD vs SNPX Comparison
SGD vs SNPX Comparison
Compare SGD & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- SNPX
- Stock Information
- Founded
- SGD 2021
- SNPX 2012
- Country
- SGD United States
- SNPX United States
- Employees
- SGD N/A
- SNPX N/A
- Industry
- SGD
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- SGD
- SNPX Health Care
- Exchange
- SGD Nasdaq
- SNPX Nasdaq
- Market Cap
- SGD 4.8M
- SNPX 5.2M
- IPO Year
- SGD N/A
- SNPX N/A
- Fundamental
- Price
- SGD $0.26
- SNPX $3.45
- Analyst Decision
- SGD
- SNPX Strong Buy
- Analyst Count
- SGD 0
- SNPX 1
- Target Price
- SGD N/A
- SNPX $14.00
- AVG Volume (30 Days)
- SGD 2.7M
- SNPX 32.7K
- Earning Date
- SGD 01-01-0001
- SNPX 08-14-2024
- Dividend Yield
- SGD N/A
- SNPX N/A
- EPS Growth
- SGD N/A
- SNPX N/A
- EPS
- SGD N/A
- SNPX N/A
- Revenue
- SGD $91,978.00
- SNPX N/A
- Revenue This Year
- SGD N/A
- SNPX N/A
- Revenue Next Year
- SGD N/A
- SNPX N/A
- P/E Ratio
- SGD N/A
- SNPX N/A
- Revenue Growth
- SGD N/A
- SNPX N/A
- 52 Week Low
- SGD $0.21
- SNPX $3.27
- 52 Week High
- SGD $10.46
- SNPX $11.48
- Technical
- Relative Strength Index (RSI)
- SGD 42.00
- SNPX 41.18
- Support Level
- SGD $0.25
- SNPX $3.38
- Resistance Level
- SGD $0.29
- SNPX $4.09
- Average True Range (ATR)
- SGD 0.03
- SNPX 0.27
- MACD
- SGD 0.00
- SNPX 0.00
- Stochastic Oscillator
- SGD 15.38
- SNPX 13.50
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.